动物造模 z-bio 2022-07-02 394

　　OBJECTIVE: To observe the protective effect of salvianolic acid A on Zucker diabetic obese rats (nephropathy) and the effect on the expression of lipoprotein-related phospholipase A2.

　　METHODS: Forty male ZDF rats aged 11-12 weeks were randomly divided into model control group, SAA 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg dose group and positive (25 mg/kg darapladib group) according to body weight and blood sugar. ) control group, 8 rats in each group, and another 8 ZL rats of the same age were selected as the normal control group, each administration group was administered once a day, and the model control group and the normal control group were administered the same volume of normal saline every day for continuous After 12 weeks, the renal microcirculation blood flow velocity of ZDF rats was measured, and the activity of Lp-PLA2 in serum, blood urea nitrogen (BUN), creatinine (creatinine, Crea), and urinary transferrin (TRF) were detected. ), microalbumin (mALB) and retinol binding protein (RBP) contents and Lp-PLA2 mRNA and protein expression in renal tissue, and renal histopathology was observed.

　　Results: Compared with the normal control group, the rats in the model control group had obvious changes in renal pathological structure and the blood flow velocity of renal microcirculation was significantly decreased (P<0.01). and RBP were significantly increased (P<0.01), and the expression of Lp-PLA2 mRNA and protein in renal tissue was increased (P<0.01); SAA and Lp-PLA2 inhibitor (darapladib) could significantly improve the changes of the above indicators, In the SAA administration group, the improvement was particularly significant in the 0.5 mg/kg and 1 mg/kg dose groups.

　　Conclusion: SAA has obvious protective effect on the kidney of ZDF rats, and its mechanism may be related to the inhibition of LpPLA2.